CGM Trial Reports Improved Glycemic Control in Noninsulin-Treated Type 2 Diabetes

Continuous glucose monitoring (CGM) improved glycemic control in adults with type 2 diabetes who were not using insulin, according to a University of Colorado Anschutz press release describing research published in the New England Journal of Medicine. The multicenter randomized controlled trial enrolled 283 adults across 22 U.S. primary care practices and followed them for 26 weeks, evaluating CGM effectiveness and safety against routine care.

CGM users spent approximately five additional hours per day within their target glucose range compared with participants receiving routine care. The between-group difference in A1c improvement was 0.9 percentage points in favor of CGM. Nearly twice as many CGM users achieved A1c below 7%, although absolute proportions were not provided in the release.

Recruitment exclusively through primary care practices makes the findings relevant to routine diabetes management. The researchers suggest the results could inform future guidelines and insurance coverage for people not using insulin; no guideline or coverage change was announced. The release does not identify the CGM device, funding source, target-range definition, baseline glycemic control, or detailed safety results. These are glycemic outcomes rather than evidence of reduced long-term diabetes complications, and the reported findings require verification against the full publication.